0001209191-18-003485.txt : 20180112 0001209191-18-003485.hdr.sgml : 20180112 20180112195610 ACCESSION NUMBER: 0001209191-18-003485 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180111 FILED AS OF DATE: 20180112 DATE AS OF CHANGE: 20180112 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MCGRATH JOHN CENTRAL INDEX KEY: 0001205442 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36548 FILM NUMBER: 18526967 MAIL ADDRESS: STREET 1: 6900 PASEO PADRE PARKWAY CITY: FREMONT STATE: CA ZIP: 94555 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Atara Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001604464 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 460920988 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 611 GATEWAY BLVD STREET 2: SUITE 900 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-278-8930 MAIL ADDRESS: STREET 1: 611 GATEWAY BLVD STREET 2: SUITE 900 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-01-11 0 0001604464 Atara Biotherapeutics, Inc. ATRA 0001205442 MCGRATH JOHN 611 GATEWAY BOULEVARD SUITE 900 SOUTH SAN FRANCISCO CA 94080 0 1 0 0 EVP & Chief Financial Officer Common Stock 2018-01-11 4 S 0 3500 20.77 D 93154 D Common Stock 2018-01-12 4 M 0 30000 11.00 A 123154 D Common Stock 2018-01-12 4 S 0 3500 22.32 D 119654 D Common Stock 2018-01-12 4 S 0 30000 25.00 D 89654 D Employee Stock Option (Right to Buy) 11.00 2018-01-12 4 M 0 30000 0.00 D 2021-10-14 Common Stock 30000 10000 D Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016. The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.70 to $20.925. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price in Column 4 is a weighted average sale price. The prices actually received ranged from $22.15 to $22.35. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price in Column 4 is a weighted average sale price. The prices actually received ranged from $25.00 to $25.025. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. 1/48th of the shares subject to the stock option vest and become exercisable each month following October 15, 2014. /s/ Kim Merritt, Attorney-in-Fact for John F. McGrath, Jr. 2018-01-12